Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
Date
2009
Authors
Al-Dasooqi, N.
Bowen, J.
Gibson, R.
Sullivan, T.
Lees, J.
Keefe, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Investigational New Drugs, 2009; 27(2):173-178
Statement of Responsibility
Noor Al-Dasooqi, Joanne M. Bowen, Rachel J. Gibson, Thomas Sullivan, Jude Lees and Dorothy M. Keefe
Conference Name
Abstract
Purpose: To characterise the gastrointestinal toxicities associated with Trastuzumab administration in HER2-overexpressing breast cancer patients. Methods: All patients (n = 46) who received Trastuzumab as a single agent or in conjunction with conventional anti-cancer treatment within the Royal Adelaide Hospital Cancer Centre from 2002–2007 were included in this study. A retrospective analysis of case-notes was conducted to investigate the toxicities associated with Trastuzumab. Results: Trastuzumab as a single agent induced toxicities following 22% of administrations. Gastrointestinal toxicities were observed following 12% of administrations and included nausea and vomiting, diarrhoea, abdominal pain and bloating. However, other prominent toxicities that were not related to the gastrointestinal tract were also observed including fatigue and lung symptoms (10.4%). Elderly patients (≥60 years) and those with metastatic disease experienced the highest frequency of toxicity. Conclusion: Trastuzumab induces a range of gastrointestinal toxicities in HER2-overexpressing breast cancer patients. These toxicities are separate to those caused by concurrent chemotherapy and/or radiotherapy.
School/Discipline
Dissertation Note
Provenance
Description
The original publication can be found at www.springerlink.com